CN Menu
Press Release
Evergreen Therapeutics, Inc. Announced to Develop EG-009 for the Treatment of Moderate to Severe COVID-19
Source:Egpharm Date: Apr,2020 Views: 189

In April 2020, Evergreen Therapeutics, Inc. announced the development of a new pipeline, EG-009, to treat the Cytokine Release Syndrome (CRS) caused by the Novel Coronavirus pneumonia.

 

Epidemiologists predict that the world will remain in a pandemic state until June 2021. The virus continues to spread at a slow rate, and intermittent lockdowns are the new normal. It is estimated that 250 million people worldwide will be infected and 1.75 million will die by June 2021.


截图-20210907133431


CRS is one of the leading causes of death in COVID-19 patients. CRS is a complex inflammatory response. During the occurrence of CRS, various cytokines such as TNF-, IL-1, IL-6, IL-12, IFN-, IFN-, McP-1, and IL-8 are produced in large quantities in body fluids. CRS can cause acute respiratory distress syndrome and multiple organ failure. CRS can occur not only in a variety of disease states, but also after organ transplantation, macromolecular drug therapy, and CAR-T product treatment. What is more dangerous is that some patients have a second cytokine storm after they leave the hospital and go home. Eg-009A, developed by Evergreen Therapeutics, Inc., will be used primarily to treat cytokine storms in hospitalized patients with COVID-19. The oral agent EG-009 is mainly used to prevent and treat the second cytokine storm in COVID-19 patients after discharge from the hospital.